Vaxart Inc
NASDAQ:VXRT

Watchlist Manager
Vaxart Inc Logo
Vaxart Inc
NASDAQ:VXRT
Watchlist
Price: 0.5992 USD -2.11% Market Closed
Market Cap: 136.3m USD
Have any thoughts about
Vaxart Inc?
Write Note

Vaxart Inc
Other Long-Term Assets

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Vaxart Inc
Other Long-Term Assets Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Other Long-Term Assets CAGR 3Y CAGR 5Y CAGR 10Y
Vaxart Inc
NASDAQ:VXRT
Other Long-Term Assets
$61m
CAGR 3-Years
324%
CAGR 5-Years
261%
CAGR 10-Years
54%
Abbvie Inc
NYSE:ABBV
Other Long-Term Assets
$8.3B
CAGR 3-Years
20%
CAGR 5-Years
44%
CAGR 10-Years
26%
Gilead Sciences Inc
NASDAQ:GILD
Other Long-Term Assets
$7.2B
CAGR 3-Years
15%
CAGR 5-Years
10%
CAGR 10-Years
23%
Amgen Inc
NASDAQ:AMGN
Other Long-Term Assets
$10.4B
CAGR 3-Years
18%
CAGR 5-Years
43%
CAGR 10-Years
21%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Other Long-Term Assets
$3.2B
CAGR 3-Years
49%
CAGR 5-Years
17%
CAGR 10-Years
95%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Other Long-Term Assets
$4.1B
CAGR 3-Years
70%
CAGR 5-Years
34%
CAGR 10-Years
31%
No Stocks Found

Vaxart Inc
Glance View

Market Cap
136.3m USD
Industry
Biotechnology

Vaxart, Inc. operates as a clinical-stage biotechnology company, which engages in the development of oral recombinant vaccines based on its Vector-Adjuvant-Antigen Standardized Technology (VAAST) oral vaccine platform. The company is headquartered in South San Francisco, California and currently employs 110 full-time employees. Its programs include tablet vaccines designed to protect against coronavirus, norovirus, seasonal influenza and respiratory syncytial virus (RSV), as well as a therapeutic vaccine for human papillomavirus (HPV). The Company’s product pipeline includes norovirus vaccine, an oral tablet vaccine, which is in a Phase Ib clinical trial with bivalent oral tablet vaccine for the GI.1 and GII.4 norovirus strains; influenza vaccine, which is in Phase II clinical trial for the treatment of H1 influenza infection; respiratory syncytial virus vaccine; and coronavirus vaccine, which is in Phase II clinical trial for the treatment of SARS-CoV-2 infection. The firm is also developing therapeutic vaccines for cervical cancer and dysplasia caused by human papillomavirus.

VXRT Intrinsic Value
0.6663 USD
Undervaluation 10%
Intrinsic Value
Price

See Also

What is Vaxart Inc's Other Long-Term Assets?
Other Long-Term Assets
61m USD

Based on the financial report for Sep 30, 2024, Vaxart Inc's Other Long-Term Assets amounts to 61m USD.

What is Vaxart Inc's Other Long-Term Assets growth rate?
Other Long-Term Assets CAGR 10Y
54%

Over the last year, the Other Long-Term Assets growth was 6 673%. The average annual Other Long-Term Assets growth rates for Vaxart Inc have been 324% over the past three years , 261% over the past five years , and 54% over the past ten years .

Back to Top